MAIA Biotechnology, Inc. filed a Form 8-K on November 17, 2026, disclosing under Item 7.01 Regulation FD that it issued a press release reporting efficacy results from its expanded Phase 2 THIO-101 study in non-small cell lung cancer.
Key Highlights
- Filing type and date: The current report was filed and dated November 17, 2026, with the same date as the earliest reported event.
- Press release title: The attached press release is entitled "MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer."
- Disclosure mechanism: The filing is made under Item 7.01 Regulation FD and the information is furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934.
- Study scope: The press release addresses an expanded Phase 2 study designated THIO-101 in non-small cell lung cancer, according to the filing.
- Signatory: The report was signed by Vlad Vitoc, Chief Executive Officer of MAIA Biotechnology, Inc.
- Exchange listing: The company's common stock trades under the symbol MAIA on NYSE American, as stated in the filing's registered-securities table.
MAIA Biotechnology Furnishes THIO-101 Phase 2 Efficacy Update Under Reg FD
MAIA Biotechnology, Inc. (NYSE American:MAIA) furnished a Form 8-K to the SEC on November 17, 2026, disclosing the issuance of a press release related to its THIO-101 clinical program. According to the filing, the press release is titled "MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer" and is attached as Exhibit 99.1.
The company disclosed the press release under Item 7.01 Regulation FD. The filing states that the information in Item 7.01, including Exhibit 99.1, "is being furnished and shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section." The filing further states the information shall not be incorporated by reference into any registration statement except as expressly stated in such a filing.
The filing includes a forward-looking statements cautionary block, which is the company's own. The company cautions that statements other than historical facts are forward-looking and "are subject to known and unknown risks, uncertainties, and other factors" that may cause actual results to differ materially. The company states it "undertakes no obligation to publicly update or revise any forward-looking statement" except as required by law. MAIA Biotechnology is identified in the filing as an emerging growth company incorporated in Delaware, with principal offices at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
What Was Disclosed
MAIA Biotechnology filed an 8-K on November 17, 2026, furnishing under Regulation FD a press release describing efficacy results from the expanded Phase 2 THIO-101 study in non-small cell lung cancer. No financial statements were included in the filing.



Please wait processing your request...